Brazil Insulin Drugs and Delivery Devices Market Report Reveals Key Insights for 2033

Brazil Insulin Drugs & Delivery Devices Market Overview in 2025

Market Size in 2024: USD 940 Million
Market Forecast in 2033: USD 1,028 Million
Market Growth Rate 2025-2033: 1%

The Brazil insulin drugs & delivery devices market is projected to grow from USD 940 million in 2024 to USD 1,028 million by 2033, registering a CAGR of 1%. Rising type-1 and type-2 diabetes prevalence, broader SUS coverage and the shift toward smart insulin pens are driving sustained demand across both public and private channels.

Brazil Insulin Drugs & Delivery Devices Market Growth Drivers

SUS Adds Smart Pens to National Essential List

The Ministry of Health included Bluetooth-enabled reusable pens in the 2025 SUS protocol, allocating BRL 480 million for 1.2 million devices. Patients now receive dose-reminder alerts and automatic glucose logging, cutting hypoglycaemia episodes by 18%. The guaranteed public procurement encourages domestic assembly, with three local plants receiving ANVISA certification and expanding production capacity within the Brazil insulin drugs & delivery devices ecosystem.

ANVISA Fast-Track Biosimilar Pathway Cuts Entry to 240 Days

The 2025 biosimilar update halves review time for insulin glargine and aspart copies, while waiving Phase III trials if EU/US approval exists. Domestic labs filed eight biosimilar applications in Q1, promising 35% price discounts. The competitive pipeline is expected to expand patient access and accelerate prescription volumes across the Brazil insulin drugs & delivery devices market.

Farmácia Popular Digital Voucher Boosts Adherence

The federal programme migrated to a fully digital wallet in March 2025, issuing instant PIX vouchers for insulin and pen needles. Within 60 days redemption rates rose to 78% from 61%, while out-of-pocket spend fell BRL 120 million nationwide. The seamless reimbursement encourages consistent therapy, directly supporting volume growth for Brazil insulin drugs & delivery devices suppliers.

Request a Free Sample Copy of the Report: https://www.imarcgroup.com/brazil-insulin-drugs-delivery-devices-market/requestsample

Brazil Insulin Drugs & Delivery Devices Market Segmentation

Drug Insights:

• Basal or Long-acting Insulins
  • Lantus (Insulin Glargine)
  • Levemir (Insulin Detemir)
  • Toujeo (Insulin Glargine)
  • Tresiba (Insulin Degludec)
  • Basaglar (Insulin Glargine)
• Bolus or Fast-acting Insulins
  • NovoRapid/Novolog (Insulin aspart)
  • Humalog (Insulin lispro)
  • Apidra (Insulin glulisine)
  • FIASP (Insulin aspart)
  • Admelog (Insulin lispro Sanofi)
• Traditional Human Insulins
  • Novolin/Mixtard/Actrapid/Insulatard
  • Humulin
  • Insuman
• Combination Insulins
  • NovoMix (Biphasic Insulin aspart)
  • Ryzodeg (Insulin degludec and Insulin aspart)
  • Xultophy (Insulin degludec and Liraglutide)
  • Soliqua/Suliqua (Insulin glargine and Lixisenatide)
• Biosimilar Insulins
  • Insulin Glargine Biosimilars
  • Human Insulin Biosimilars

Device Insights:

• Insulin Pens
  • Cartridges in Reusable Pens
  • Disposable Insulin Pens
• Insulin Pumps
  • Insulin Pump Devices
  • Insulin Pump Reservoirs
  • Insulin Infusion Sets
• Insulin Syringes
• Insulin Jet Injectors

Regional Insights:

• Southeast
• South
• Northeast
• North
• Central-West

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Request Customization: https://www.imarcgroup.com/request?type=report&id=13708&flag=E

Brazil Insulin Drugs & Delivery Devices Market News

• Mar 2025: Biomm receives ANVISA approval for the first domestically produced insulin glargine biosimilar, priced 30% below imported brands.
• Apr 2025: The Ministry of Health rolls out a tele-endocrinology platform that syncs smart-pen data with public clinics, reducing travel costs for 1.2 million patients.
• May 2025: Novo Nordisk partners with a local med-tech to manufacture reusable pen injectors in Minas Gerais, targeting 30% local content by 2027.
• Jun 2025: SUS pilots a subscription model for continuous glucose monitors, integrating readings with digital insulin-dose calculators.

Key highlights of the Report:

• Market Performance (2019-2024)
• Market Outlook (2025-2033)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendations
• Historical, Current and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.